Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.86M | Year: 2017
All chemicals whether they are drugs, cosmetics, agrochemicals or others need to be tested for their safety to man and the environment. The use of whole animal studies for the prediction of adverse effects in man, is problematic due to species dependent effects, high costs and a large burden to animals in terms of numbers and suffering. While there have been major improvements in human in vitro and in silico techniques, there is still a lack of an integrated risk assessment platform. The in3 proposal aims to significantly further the development of animal-free chemical and nanomaterial (NM) safety evaluation by creating a scientific and training program aimed at integrating human in vitro testing with computational approaches. The project will focus on human induced pluripotent stem cells (hiPSC) derived tissues, including liver, kidney, brain, lung and vasculature and to utilise mechanistic toxicology, quantitative adverse outcome pathways, biokinetics, cheminformatics and modelling approaches to derive testable prediction models. hiPSC present the major advantages provide non-cancerous derived tissues with identical genetic backgrounds. All Early Stage Researchers (ESRs) will work towards the same goal, utilising the same chemicals, donor cells, assays and software packages. All data will be centrally housed in standardised formats, appropriately annotated and linked with protocols and material information. While ESRs will hone their skills in their own field of expertise, they will also collaborate to create an in depth safety evaluation testing platform for the chosen test compounds. By interaction, problem solving, training and secondments over the three years, they will acquire a unique set of interdisciplinary skills for chemical and NM safety assessment. The project aims to accelerate the realisation of animal-free safety assessment and to graduate 15 PhD students with the ideal skill sets to carry out the strategy designed in in3 in the near future.
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2015-ETN | Award Amount: 3.07M | Year: 2015
The brain barriers function to protect the central nervous system (CNS) from neurotoxic compounds. By the same traits they unfortunately block delivery of drugs to the CNS thus hindering proper diagnosis and effective treatment of neurological disorders including Alzheimers disease and multiple sclerosis. The unusual complexity of the brain barriers has severely hampered progress in the market of CNS targeting therapeutics. BtRAIN bridges this gap by creating particular knowledge on vertebrate brain barrier signature genes and their specific roles in regulating brain barrier function in development, health, ageing and disease. Brain barrier signature genes will be identified by combining cross-species and cross-system brain barrier transcriptome analysis with dedicated bioinformatics. These data will be made available for brain barrier datamining in the userfriendly online platform BBBHub. Within BtRAIN, the side-by-side comparison of a unique and broad armamentarium of different vertebrate in vitro and in vivo brain barrier models will allow to develop and validate particular in vitro brain barrier models that are suited to reliably predict brain barrier function in vivo. Combined with an accompanying in depth analysis of the pathological alterations of the brain barriers during neurological disorders BtRAIN will create unique knowledge to overcome the unmet need for the development of diagnostic and therapeutic tools able to breach the brain barriers. In BtRAIN 12 academic, 6 non-academic partners and 1 European network will jointly train young researchers at unique interfaces of brain barrier research, bioinformatics, business development and science communication for an international research or entrepreneur career. To create this expert pool is the motivation for the involved partners as it will advance the Euopean capacity to bring innovative approaches to the untapped potential of the CNS therapeutic market.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2007-1.3-1 | Award Amount: 16.43M | Year: 2008
The overall aim of Predict-IV is to develop strategies to improve the assessment of drug safety in the early stage of development and late discovery phase, by an intelligent combination of non animal-based test systems, cell biology, mechanistic toxicology and in-silico modelling, in a rapid and cost effective manner. A better prediction of the safety of an investigational compound in early development will be delivered. Margins-of-safety will be deduced and the data generated by the proposed approach may also identify early biomarkers of human toxicity for pharmaceuticals. The results obtained in Predict-IV will enable pharmaceutical companies to create a tailored testing strategy for early drug safety. The project will integrate new developments to improve and optimize cell culture models for toxicity testing and to characterize the dynamics and kinetics of cellular responses to toxic effects in vitro. The target organs most frequently affected by drug toxicity will be taken into account, namely liver and kidney. Moreover, predictive models for neurotoxicty are scarce and will be developed. For each target organ the most appropriate cell model will be used. The approach will be evaluated using a panel of drugs with well described toxicities and kinetics in animals and partly also in humans. This approach will be highly advantageous as it will allow a direct comparison between the in vivo to the in vitro data. A parallel analysis of several dynamic and kinetic models with a broad spectrum of endpoints should allow for the identification of several relevant biomarkers of toxicity. Inter-individual susceptibilities will be taken into account by integrating the polymorphisms of the major drug metabolizing enzymes and correlating the observed effects in the human cell models with their genotype. Environmental influences on cellular toxicity to these compounds will also be evaluated using hypoxic stress as a relevant test model.
Pivert, French National Center for Scientific Research and University of Artois | Date: 2014-11-07
The invention relates to a method for the hydroformylation of triglycerides by homogeneous catalysis in the presence of at least one substituted cyclodextrin, said method comprising a step a) of combining, under agitation, at least one catalyst, water, at least one unsaturated triglyceride and said substituted cyclodextrin, in the presence of gaseous hydrogen and carbon monoxide, said step being carried out in reactive conditions allowing the formation of an emulsion during the agitation and a decanting of the products once the agitation has stopped.
Agency: Cordis | Branch: FP7 | Program: CP | Phase: ICT-2007.8.0 | Award Amount: 2.70M | Year: 2009
TAILPHOX project addresses the design and implementation of Silicon phoXonic crystal structures that allow a simultaneous control of both photonic and phononic waves. The final goal is to push the performance of optical devices well beyond the state of the art by this radically new approach. By merging both fields (nanophotonics and nanophononics) within a same platform, novel unprecedented control of light and sound in very small regions will be achieved. The project will cover from the development of theoretical and numerical tools to deal simultaneously with light and sound to the application to three high-impact scenarios in the field of ICT: i) phonon-assisted light emission in Silicon, ii) control of photon speed (delay and storage) by SBS in Silicon photonic chips, and iii) realization of highly-sensitive dual phoXonic sensors.
Agency: Cordis | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2015 | Award Amount: 1.71M | Year: 2016
Although computer animation technology has been extensively used for films and games, it remains largely labour-intensive and expensive, with recent blockbuster films (e.g. Avatar, Gravity) costing around $1 million per minute of footage. A lot of research efforts and technological breakthroughs are therefore necessary if it is to be widely applied to many low-cost applications, such as archiving and reproducing style-preserved intangible cultural heritage (ICH) contents. The project AniAge is designed to answer this very challenge, using Southeast Asian ICH as the main application. Southeast Asian ICHs, e.g. local dances and puppetry, are visually and culturally rich, but are unfortunately disappearing due to the globalized modernization. The overall aim of AniAge is two-fold. The first is to develop novel techniques and tools to reduce the production costs and improve the level of automation without sacrificing the control of the artists, in order to preserve the performing art related ICHs of Southeast Asia. This involves capturing and processing versatile visual performance data, which are heterogeneous in nature and gigantic in quantity. Two areas of technological innovation are aimed to be made, which are novel algorithms for 3D computer animation; and visual asset management with data analytics and machine learning techniques. The second is to promote knowledge exchange and dissemination between EU and Southeast Asian partners, with a view to fostering researchers and spreading knowledge. This will be achieved by having researchers participating in the well-designed research projects, workshops, seminars and open lectures. This consortium consists of six partners, two from the EU and four from Southeast Asia. Four work packages are designed, three for technological developments (digitalizing traditional performing arts - DigAge, digital asset management - ManD and stylized animation production - AniX) and one for dissemination (Dissem).
Agency: Cordis | Branch: FP7 | Program: JTI-CS | Phase: JTI-CS-2011-1-SAGE-02-008 | Award Amount: 292.51K | Year: 2012
The project objective is to evaluate the reliability of motor winding technologies able to work at high temperatures. To achieve this goal within the time define in the Clean Sky call sheet, it is necessary to rely on existing technologies, which offer opportunities for rapid implementations on conventional machines, while opening new opportunities towards higher temperatures with innovative technologies. Three sets of technologies will be studied: - The technologies based on enamelled wires associated to polymer impregnation varnishes. - Technologies based on wires wrapped with glass fibber associated to impregnations made with epoxy resins. - The insulation technologies based on ceramics, which offer potential prospects for very high temperatures. The three sets of technologies will be tested for increasing temperatures on representative test vehicles (twisted pairs, transformer coils and motorettes) involving measurement systems able to get the main parameters of the insulation system (DC and AC leakage currents, partial discharge inception voltage, breakdown voltage, ). The analysis of changes in recorded parameters during the test campaigns will estimate the maximum permissible temperature in the heart of the winding for each technology. These data, combined with constraints of implementation of each technology will define recommendations for the design of electrical machines able to operate at high temperatures for each selected technology. The part relating to the use of ceramic insulations opens the way to a major technological leap. With such materials, the maximum operating temperature of electrical machines will no longer be imposed by the winding insulation system but by other parts (magnetic or mechanical), consequently new design methods will have to be developed. It is therefore important to put this new approach against the best we might obtain from other technologies by proposing solutions applicable in the short term.
Fenart L.,University of Artois
Current Alzheimer research | Year: 2013
Ever since amyloid-β (Aβ) peptides were first identified in cerebral plaques in patients with Alzheimer's disease (AD), much research work has focused on the complex mechanisms through which these peptides are synthesized, transported and degraded. Although new information emerges on a regular basis, we consider that the importance of the blood-brain barrier (BBB) in the pathogenesis of AD has been underestimated. In fact, there are a number of obstacles that make it difficult to convince specialists in AD that the BBB indeed plays a key role in this disease: these include the complex physiology of the BBB and the technical difficulty of studying the barrier in vivo and reproducing its main properties in vitro. With these considerations in mind, the present review sets out summarize our current knowledge about the physiology of the BBB and describe recent research findings on the barrier's role in Aβ peptide proteostasis and thus in the mechanism of AD.
Marquis P.,University of Artois
IJCAI International Joint Conference on Artificial Intelligence | Year: 2011
We study the existential closures of several propositional languages L considered recently as target languages for knowledge compilation (KC), namely the incomplete fragments KROM-C, HORN-C, K/H-C, renH-C, AFF, and the corresponding disjunction closures KROM-C[V], HORN-C[V], K/H-C[V], renH-C[V], and AFF[V]. We analyze the queries, transformations, expressiveness and succinctness of the resulting languages L[∃] in order to locate them in the KC map. As a by-product, we also address several issues concerning disjunction closures that were left open so far. From our investigation, the language HORN - C[V, ∃] (where disjunctions and existential quantifications can be applied to Horn CNF formulae) appears as an interesting target language for the KC purpose, challenging the influential DNNF languages.
University of Artois | Date: 2014-03-26
The present disclosure relates to a method for obtaining human brain-like endothelial cells by contacting a population of cells isolated from stem cells with a differentiation medium to obtain endothelial cells and co-culturing said endothelial cells with pericytes, with cells of the neurovascular unit or with a pericytes conditioned medium, to obtain brain-like endothelial cells. The present disclosure also relates to the use of the brain-like endothelial cells as an in vitro model of human blood-brain barrier and a kit for measuring blood-brain barrier permeability of a substance, comprising in vitro human endothelial cells.